Louis Frederic Diehl, MD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
Phone (919) 668-1000
Email address louis.diehl@duke.edu

Research interests include Hodgkin disease, non-Hodgkin lymphomas, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia.

In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Walter Reed Army Medical Center, 1978 - 1981
  • Medical Resident, Medicine, Walter Reed Army Medical Center, 1975 - 1978
  • M.D., Georgetown University, 1975

Publications

Rao, Arati, David A. Rizzieri, Eduardo Vanegas, Joseph O. Moore, Jon P. Gockerman, Louis F. Diehl, Donna Adams, Julie Warzecho, and Carlos Decastro. “Pilot Study of Sorafenib for Myelodysplastic Syndrome.” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.

Scholars@Duke

Rao, Arati, Ghazi Khan, David A. Rizzieri, Joseph O. Moore, Jon P. Gockerman, Louis F. Diehl, Anne W. Beaven, Donna Adams, Julie Warzecho, and Carlos Decastro. “Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS.” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.

Scholars@Duke

Dorth, Jennifer A., Leonard R. Prosnitz, Gloria Broadwater, Louis F. Diehl, Anne W. Beaven, R Edward Coleman, and Chris R. Kelsey. “Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging..” Int J Radiat Oncol Biol Phys 84, no. 3 (November 1, 2012): 762–67. https://doi.org/10.1016/j.ijrobp.2011.12.067.

PMID
22420972
Full Text

Rao, A. V., D. A. Rizzieri, C. M. DeCastro, L. F. Diehl, A. S. Lagoo, J. O. Moore, and J. P. Gockerman. “Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML.” Journal of Geriatric Oncology 3, no. 3 (July 1, 2012): 220–27. https://doi.org/10.1016/j.jgo.2012.02.002.

Full Text

Lanasa, Mark C., Patricia H. Davis, Michael Datto, Zhiguo Li, Jon P. Gockerman, Joseph O. Moore, Carlos M. DeCastro, et al. “Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia..” Leuk Lymphoma 53, no. 2 (February 2012): 218–24. https://doi.org/10.3109/10428194.2011.610012.

PMID
21827374
Full Text

Kelsey, C. R., A. W. Beaven, L. F. Diehl, and L. R. Prosnitz. “Combined-modality therapy for early-stage Hodgkin lymphoma: Maintaining high cure rates while minimizing risks.” Oncology (United States) 26, no. 12 (January 1, 2012).

Scholars@Duke

Beaven, Anne W., David A. Rizzieri, Zachary Powell, Zhiguo Li, Peggy Alton, Julie Warzecho, Louis F. Diehl, Joseph O. Moore, Carlos Manuel de Castro, and Jon P. Gockerman. “High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma.” In Blood, 118:1152–1152. AMER SOC HEMATOLOGY, 2011.

Scholars@Duke

Weinberg, J Brice, David J. DiLillo, Yohei Iwata, Takashi Matushita, Karen M. Matta, Guglielmo M. Venturi, Giandomenico Russo, et al. “Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells.” In Blood, 118:132–33. AMER SOC HEMATOLOGY, 2011.

Scholars@Duke

Morris, Tod A., David A. Rizzieri, Carlos M. de Castro, Louis F. Diehl, Jon P. Gockerman, Anand S. Lagoo, Joseph O. Moore, and Arati V. Rao. “Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia.” In Blood, 118:1532–33. AMER SOC HEMATOLOGY, 2011.

Scholars@Duke

Christensen, Dale J., Youwei Chen, Jessica Oddo, Karen M. Matta, Jessica Neil, Evan D. Davis, Alicia D. Volkheimer, et al. “SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target..” Blood 118, no. 15 (October 13, 2011): 4150–58. https://doi.org/10.1182/blood-2011-04-351072.

PMID
21844565
Full Text

Pages